Systems-level immune modulation

Systems-level immune modulation refers to a therapeutic strategy that targets the immune system as an integrated, dynamic network rather than focusing on a single isolated molecular pathway. This approach aims to recalibrate the complex interplay between various immune cell types—such as T cells, B cells, and myeloid cells—and their signaling molecules, including cytokines and chemokines (Davis et al., Nature Immunology, 2017). By influencing the system as a whole, these interventions can address multifactorial diseases like cancer, where the immune environment is often suppressed, or autoimmune disorders, where the system is pathologically overactive. Common therapeutic modalities include immune checkpoint inhibitors, systemic cytokine therapies, and chimeric antigen receptor (CAR) T-cell therapies, all of which trigger broad effects across the immune landscape (NCI, 2023). While highly effective, this systems-level approach carries significant risks of systemic toxicity, such as cytokine release syndrome (CRS) and immune-related adverse events (irAEs), due to the widespread nature of the modulation. Consequently, the field increasingly relies on high-throughput 'omics' data and computational modeling to identify predictive biomarkers and optimize therapeutic windows (Koutsakos et al., Current Opinion in Virology, 2019).

Other names

Systemic immune modulationSystems immunology-based therapyNetwork-level immune regulationImmune system engineering

Systems-level immune modulation involves the broad alteration of immune signaling networks and cellular interactions to shift the systemic immune state from a pathological to a therapeutic equilibrium (Davis et al., Nature Immunology, 2017). This is achieved by targeting high-level regulatory nodes, such as immune checkpoints or cytokine receptors, which results in a cascade of downstream effects across multiple immune cell lineages (Koutsakos et al., Current Opinion in Virology, 2019).